Taken together, our findings identify clinically important subgroups of NF1-mutant, IDH wild-type glioblastomas and delineate mechanisms of MEK inhibitor response, informing the development of synergistic therapies for NF1-mutant glioblastomas. The gene discussed is NF1; the disease is glioblastoma.